Research
Hormonal
Regular monitoring of cardiovascular risk factors (weight, BMI, waist circumference, blood pressure, lipids, glucose) is recommended for all women with PCOS, regardless of age, due to increased prevalence of risk factors.
Get your blood pressure, cholesterol, and blood sugar checked regularly, even if you feel healthy. PCOS increases your risk for heart issues, so monitoring these numbers annually or as advised by your doctor is crucial for long-term health.
ModerateSupportsLOW confidence
All women with PCOS should be assessed for cardiovascular risk factors and global CVD risk
Why this rating
Rated as Clinical Consensus Recommendation (CCR) with GRADE symbol ⊕⊕○○ (Low quality evidence).
Source
Recommendations from the international evidence‐based guideline for the assessment and management of polycystic ovary syndrome
Helena Teede et al. · Clinical Endocrinology · 2018
DOI 10.1111/cen.13795
clinical_guidelineCited 1,821×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Multicomponent lifestyle interventions (diet, exercise, behavioral strategies) are recommended for all women with PCOS and excess weight to achieve 5-10% weight loss, which significantly improves hormonal outcomes, insulin resistance, and quality of life.Moderate
- Routine screening for Obstructive Sleep Apnea (OSA) in PCOS is not recommended for the purpose of improving cardiometabolic risk, as there is inadequate evidence for metabolic benefits of OSA treatment in PCOS.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →